Robin Besuyen
Leiden, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study.
Journal: RMD open
Published: August 08, 2024
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH.
Journal: Journal of hepatology
Published: July 23, 2024
Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial.
Journal: JAMA ophthalmology
Published: July 18, 2024
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.
Journal: Annals of the rheumatic diseases
Published: February 13, 2023
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis.
Journal: Rheumatology and therapy
Published: July 06, 2022
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
Journal: Modern rheumatology
Published: November 24, 2021
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial.
Journal: Intestinal research
Published: October 21, 2021
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Journal: Annals of the rheumatic diseases
Published: June 22, 2021
Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial.
Journal: Rheumatology (Oxford, England)
Published: June 11, 2021
Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial).
Journal: Rheumatology (Oxford, England)
Published: March 23, 2021
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.
Journal: The Journal of rheumatology
Published: January 14, 2021
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Journal: Lancet (London, England)
Published: December 18, 2020
Last Updated: 09/26/2026